SABCS Marks 40 Years

Kent Osborne, MD, a codirector of SABCS, wrote a guest post for Cancer Research Catalyst in 2015 that details the symposium’s growth. We’re happy to present it again. Check back with Cancer Research Catalyst frequently for updates from SABCS, which will take place Dec. 5-9.

Read More

Treating DNA Repair-deficient Breast Cancers

Several clinical trials are underway in which PARP inhibitors are being tested in breast cancers, mostly triple-negative breast cancers, because they often harbor BRCA mutations and DNA repair deficiencies. Emerging studies show that the benefit of PARP inhibitors could extend beyond breast cancers with germline BRCA mutations.

Read More

FDA Approves New Treatment Option for Breast Cancer

Last week, the U.S. Food and Drug Administration (FDA) provided some good news for the breast cancer community just days before the start of breast cancer awareness month when it added a new molecularly targeted therapeutic to the armamentarium for oncologists treating patients with breast cancer: abemaciclib (Verzenio).

Read More

News from the Cancer Centers: How DCIS Becomes Invasive Breast Cancer

Earlier this year, a study published in Cancer Discovery, a journal of the American Association for Cancer Research (AACR), explored the question of how preinvasive breast tumors become invasive. The study’s lead author, Kornelia Polyak, MD, PhD, discussed the findings in an article published by Inside the Institute, a publication of Dana-Farber Cancer Institute.

Read More

FDA Approves a New HER2-targeted Therapeutic for Breast Cancer

Earlier this week, the U.S. Food and Drug Administration (FDA) approved a new molecularly targeted therapeutic called neratinib (Nerlynx) for treating certain patients with HER2-positive breast cancer. Specifically, the FDA approved neratinib for reducing disease recurrence in patients with early-stage HER2-positive breast cancer who have completed postsurgery (adjuvant) treatment with trastuzumab (Herceptin) and whose disease has not progressed.

Read More

New Therapeutic Approved by FDA to Treat Breast Cancer

Earlier this week, the U.S. Food and Drug Administration approved the molecularly targeted therapeutic ribociclib (Kisqali) for use in combination with any aromatase inhibitor for initial treatment of postmenopausal women with a hormone receptor (HR)–positive, HER2-negative, advanced breast cancer.

Read More

SABCS 2016: Extended Letrozole Therapy May Have Limited Benefits

Data presented at the San Antonio Breast Cancer Symposium showed that five additional years of the aromatase inhibitor (AI) therapy letrozole (Femara) following an initial five years of AI-based adjuvant hormone therapy did not significantly improve survival outcomes in postmenopausal women with early-stage HR-positive breast cancer. The additional five years did improve some outcomes related to recurrence.

Read More